These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12087353)

  • 1. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.
    Visser LE; Penning-van Beest FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Clin Pharmacol Ther; 2002 Jun; 71(6):496-502. PubMed ID: 12087353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants.
    Visser LE; Bleumink GS; Trienekens PH; Vulto AG; Hofman A; Stricker BH
    Br J Haematol; 2004 Oct; 127(1):85-9. PubMed ID: 15384981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.
    Visser LE; Penning-van Bees FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Thromb Haemost; 2002 Nov; 88(5):705-10. PubMed ID: 12428081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation.
    Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH
    Thromb Haemost; 2001 Aug; 86(2):569-74. PubMed ID: 11522005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon.
    Visser LE; Penning-van Beest FJ; Wilson JH; Vulto AG; Kasbergen AA; De Smet PA; Hofman A; Stricker BH
    Br J Clin Pharmacol; 2004 Apr; 57(4):522-4. PubMed ID: 15025752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.
    Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH
    Clin Pharmacol Ther; 2001 Jun; 69(6):451-7. PubMed ID: 11406743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
    Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
    Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment.
    Teichert M; van Noord C; Uitterlinden AG; Hofman A; Buhre PN; De Smet PA; Straus S; Stricker BH; Visser LE
    Br J Haematol; 2011 May; 153(3):379-85. PubMed ID: 21418179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miconazole and nystatin used as topical antifungal drugs interact equally strongly with warfarin.
    Kovac M; Mitic G; Kovac Z
    J Clin Pharm Ther; 2012 Feb; 37(1):45-8. PubMed ID: 21332566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Miconazole oral gel enhances acenocoumarol anticoagulant activity: a report of three cases.
    Ortín M; Olalla JI; Muruzábal MJ; Peralta FG; Gutiérrez MA
    Ann Pharmacother; 1999 Feb; 33(2):175-7. PubMed ID: 10084413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
    Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
    Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prolonged diminished effect of coumarin derivatives after use of rifampicin].
    Harmsze AM; Deneer VH; Wiltink EH
    Ned Tijdschr Geneeskd; 2007 Sep; 151(35):1945-9. PubMed ID: 17907547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of acenocoumarol during vaginal administration of miconazole.
    Lansdorp D; Bressers HP; Dekens-Konter JA; Meyboom RH
    Br J Clin Pharmacol; 1999 Feb; 47(2):225-6. PubMed ID: 10190660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.